BOURSE:POXEL

Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 30, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, ULF, Senior, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, USD, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, Communication, AMN, IRIS, Scientific communication, Sumitomo Pharma, United States patent law, SGLT2, VLCFA, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Cryptocurrency, Imeglimin, EUR, Euronext

These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.

Key Points: 
  • These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • As of June 30, 2023, cash and cash equivalents were EUR 7.6 million (USD 8.2 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference

Retrieved on: 
Tuesday, July 18, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, NASH, AMPK, DSM-IV codes, Adenosine, Polycystic kidney disease, CEST, Fatty liver disease, ADPKD, Conference, Autosome, Pharmaceutical industry, Cryptocurrency, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the upcoming H.C. Wainwright 2nd Annual Kidney Conference , to be held virtually on July 25, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the upcoming H.C. Wainwright 2nd Annual Kidney Conference , to be held virtually on July 25, 2023.
  • Thomas Kuhn, CEO, and members of the management team of Poxel, will be available for one-on-one virtual meetings on July 25, 2023.
  • The Company’s virtual presentation is scheduled the same day at 9:30 am ET (3.30 pm CEST) and will focus on PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

Poxel, winner of the 2023 edition of the I-nov contest

Retrieved on: 
Wednesday, July 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, AMN, Male, State, Ministry of Culture (Spain), NASH, Adrenoleukodystrophy, Life, Marketing, Sovereignty, ALD, DSM-IV codes, Energy transition, Ministry, Ministry of Ecological Transition (France), Patient, Fatty liver disease, Marshal of France, Estonia, Investment, Ministry of Territorial Cohesion, Education, Ministry of Higher Education, Science, Research and Innovation, SME, Pharmaceutical industry, Renewable energy, Euronext, Culture, Research

This distinction is a recognition of the potential of the Company's drug candidates in development for this indication, PXL770 and PXL065.

Key Points: 
  • This distinction is a recognition of the potential of the Company's drug candidates in development for this indication, PXL770 and PXL065.
  • These studies are ready to be launched in adult male patients with adrenomyeloneuropathy (AMN), the most common form of ALD, subject to additional funding, which the Company is currently working on.
  • It selects, within the framework of a procedure encouraging competition, innovative projects with particularly high potential for the French economy.
  • The i-Nov competition, funded by the French State via France 2030 plan, is operated by Bpifrance in collaboration with ADEME.

Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris

Retrieved on: 
Friday, June 30, 2023
Biotechnology, Pharmaceutical, Health, Exercise, NASH, IRIS, DSM-IV codes, Prospectus, URD, ORA, Euronext Paris, Fatty liver disease, AMF, Security (finance), Euronext

POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces that the Autorité des Marchés Financiers (AMF) approved today a Prospectus for the admission of new shares of the Company that have been and may further be issued upon exercise of bonds redeemable in shares (ORA) or bonds redeemable in new or existing ordinary shares (ORANE) that already been issued or that may further be issued pursuant to the financing agreements entered into with IRIS, respectively on August 5, 2022 and March 22, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces that the Autorité des Marchés Financiers (AMF) approved today a Prospectus for the admission of new shares of the Company that have been and may further be issued upon exercise of bonds redeemable in shares (ORA) or bonds redeemable in new or existing ordinary shares (ORANE) that already been issued or that may further be issued pursuant to the financing agreements entered into with IRIS, respectively on August 5, 2022 and March 22, 2023.
  • The Prospectus has been published to enable the admission on Euronext Paris of these new shares of the Company when their number will exceed 20% of the number of existing ordinary shares of the Company as from the date of the issuance of the new shares that occurred upon the first redemption of bonds redeemable in shares (ORA) on August 9, 2022.
  • The Prospectus approved by the AMF under number 23-252 consists of:
    the 2022 Universal Registration Document of the Company filed with the AMF on April 28, 2023 under number D.23-0393 (the “URD”),
    the amendment to the 2022 URD filed with the AMF on June 29, 2023 under number D.23-0393-A01,
    This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, any securities of the Company in any jurisdiction.
  • Copies of the Prospectus are available free of charge on the website of the Company ( www.poxelpharma.com ) and the AMF ( www.amf-france.org ) and at the registered office of the Company, 259/261 Avenue Jean Jaurès – Immeuble le Sunway – 69007 Lyon, France.

Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting

Retrieved on: 
Friday, June 23, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, NASH, Mercure (hotel), Bank statement, Policy, DSM-IV codes, Fatty liver disease, Management, Euronext

POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2023.
  • The meeting was held at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France.
  • Shareholders also approved the renewal of Mr. Mohamed Khoso Baluch, Mr. Thomas Kuhn et Ms. Pascale Boissel as Board members.
  • Details on the voting results, as well as the presentation that was made during the meeting, will be available later today on the Company’s website, in the Investors / Shareholder Info / Annual General Meeting Documents section .

Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy

Retrieved on: 
Thursday, June 15, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, AMN, Male, ULF, NASH, Adrenoleukodystrophy, ALD, Scientific communication, DSM-IV codes, Patient, Fatty liver disease, Leukodystrophy, R, POC, Pharmacology, Conference, TZD, Pharmaceutical industry, Euronext

Poxel remains committed to discover, develop, and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology, starting with ALD.

Key Points: 
  • Poxel remains committed to discover, develop, and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology, starting with ALD.
  • PXL770 and PXL065 have demonstrated preclinically their efficacy in adrenomyeloneuropathy (AMN) and cerebral ALD (c-ALD) in mouse and human models1.
  • In line with his mission to bring therapeutic options to treat ALD, Poxel recently supported the Alex Leukodystrophy Charity during their Community Weekend, which took place from April 28th to May 1st in Birmingham, England.
  • This event brings together leukodystrophy sufferers and their families, alongside doctors, researchers and scientists from around the world to discuss leukodystrophies.

Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Adrenoleukodystrophy, Prescription, Imeglimin, Adenosine, Plasma, Journal, JPY, Patient, Serono, Merck, POC, Sumitomo Group, Disease, Male, Business development, FY, Pharmacokinetics, Autosomal dominant polycystic kidney disease, American Association for the Study of Liver Diseases, USD, European Commission, Polycystic kidney disease, Kidney International, HIV disease progression rates, Fatty liver disease, ADPKD, FDA, IPF, Safety, Abstract, DPP4, ALD, ODD, JDS, Merck Serono, Biomarker, DSM-IV codes, AMN, Non-U.S. operators of the M60 Patton, IRIS, Sumitomo Pharma, SGLT2, VLCFA, Life Sciences (journal), Regulation of tobacco by the U.S. Food and Drug Administration, Food, Autosome, Pharmaceutical industry, Bank, Management, EUR, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “This quarter we successfully restructured our debt obligations and increased our financial flexibility with a new equity-linked financing with IRIS.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • As of March 31, 2023, cash and cash equivalents were EUR 10.6 million (USD 11.6 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023

Retrieved on: 
Tuesday, May 16, 2023
Research, Diabetes, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, NASH, Mercure Hotel Canberra, Annual, Mass meeting, Annual general meeting, DSM-IV codes, Fatty liver disease, Commercial, Proxy, Medical device, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at 9 am CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at 9 am CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France.
  • The meeting notice, the convening brochure, the 2022 Universal Registration Document and the other documents and information mentioned in Article R.22-10-23 of the French Commercial code will be available to shareholders on the Company’s website at least 21 days before the Meeting at the following link: https://www.poxelpharma.com/en_us/investors/shareholder-information/annu...
    Shareholders may vote in person on the day of the Meeting, but may also vote by mail or by proxy without attending the Meeting in person, as follows:
    by mail using the voting form; or
    by giving proxy to the Chairman of the General Meeting or to any other individual or legal entity.
  • The detailed procedures for participating remotely and sending written questions beforehand are available in the meeting notice n°58, which was published in the BALO (French legal gazette) dated May 15, 2023.
  • The results and presentation for the 2023 Annual General Meeting will be available on Poxel’s website www.poxelpharma.com in the Investors/ Shareholder Information/ Annual General Meeting Documents section after the Meeting.

Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales

Retrieved on: 
Monday, May 15, 2023
Research, Diabetes, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Abstract, DPP4, FY, NASH, Sumitomo Pharma, JDS, Merck Serono, Prescription, Imeglimin, SGLT2, DSM-IV codes, EUR, JPY, Patient, Fatty liver disease, Serono, Merck, Sumitomo Group, Pharmaceutical industry, Video game, Euronext

As a result, for Sumitomo’s FY 2022, TWYMEEG gross sales reached JPY 2.2 billion (EUR 15.0 million)3, exceeding Sumitomo’s most recent FY 2022 forecast4 by 22%.

Key Points: 
  • As a result, for Sumitomo’s FY 2022, TWYMEEG gross sales reached JPY 2.2 billion (EUR 15.0 million)3, exceeding Sumitomo’s most recent FY 2022 forecast4 by 22%.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • As part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of TWYMEEG, independent of the level of sales.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.

Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Fatty liver disease, NASH, Conference, DSM-IV codes, Pharmaceutical industry, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the JMP Securities Life Science Conference, to be held in New York, NY, Monday, May 15, and Tuesday, May 16, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the JMP Securities Life Science Conference, to be held in New York, NY, Monday, May 15, and Tuesday, May 16, 2023.
  • Thomas Kuhn, CEO of Poxel, will be available for one-on-one virtual meetings on May 15, 2023.
  • The Company’s virtual presentation is scheduled for May 15 at 12:30 pm ET.